相关实验视频
Updated: Jul 11, 2026
09:53
In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
16.5K
评估LeishPepThera (PepA) 作为Leishmania major感染的免疫疗法
Shweta Khandibharad1, Shailza Singh1,2
1Systems Medicine Laboratory, BRIC - National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU Campus, Pune 411007, India.
iScience
|December 16, 2025
概括
一种新疗法,酸A (PepA),有效地准SHP-1来对抗皮肤莱什曼病. 这种方法重新平衡免疫信号,减少寄生虫负载,并为CL提供了有前途的新治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 皮肤莱什曼病 (CL) 的发病过程涉及免疫失调,特别是介质素-12 (IL-12) 和介质素-10 (IL-10) 轴.
- Src同质性2域含有蛋白质氨酸酸酶 (SHP-1) 的活性通过调节这种免疫轴来促进寄生虫的生存.
研究的目的:
- 设计和评估AI驱动的治疗,针对SHP-1进行CL治疗.
- 为了研究SHP-1抑制的免疫调节作用,在一个*Leishmania大*感染模型中.
主要方法:
- 人工智能被用来设计针对SHP-1的类.
- 甲 (PepA) 在*Leishmania major*感染模型中进行了评估.
- 评估了SHP-1抑制,NFAT5转位,氧化 (NO) 生产,巨细胞极化,细胞因子 (IL-12,IL-10) 和寄生虫负载.
主要成果:
- 甲证明了强大的SHP-1抑制,增强了NFAT5转位,并通过iNOS上调增加了NO的产生.
- 佩帕诱导了M1巨细胞,恢复了IL-12水平,抑制了IL-10表达,并显著减少了寄生虫负担.
- 该重新平衡了宿主免疫信号通路,这对于清除寄生虫至关重要.
结论:
- 甲 (LeishPepThera) 是一种有前途的免疫治疗候选人,用于皮肤Leishmaniasis.
- 用PepA针对SHP-1提供了一种新的策略,以重新平衡宿主免疫力和清除*Leishmania*寄生虫.
更多相关视频
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.5K
06:57In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
8.6K
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...